“三抗”对乙型肝炎肝衰竭生存者的干预治疗与随访

Abstract
Figure/Table
References (25)
Related Citation (14)

Download: PDF (622 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the curative effect of anti-virus, anti-inflammation and anti-fibrosis (“three antibodies”) on the survivors of hepatitis B liver failure. Methods From January 2016 to January 2018, 240 cases of hepatitis B liver failure survivors were confirmed in the Department of Spleen and Stomach Liver disease of Guangxi International Zhuang Medical Hospital, liver Disease Center of the First Affiliated Hospital of Guangxi University of Chinese Medicine, and the Teng County Hospital of Traditional Chinese Medicine, Wuzhou City, Accordance with 1:1:2 principle, they were divided into group A (simple antivirus, n = 60), group B (antivirus combined with compound Yiganling Capsules, n = 60), and group C (“ three anti-virus ”combined treatment, namely antivirus combined with compound Yiganling Capsules and Liangan Chemical fiber granule, n = 120) by random number table method. The biochemical responses, hepatic fibrosis indexes, HBeAg, HBeAb, HBeAg/Ab conversion rates and liver tissue score of the three groups before and after treatment were analyzed. Results After 12 and 24 months of treatment, the biochemical response index cereal third transaminase (ALT), total bilirubin (TBil) and albumin in the three groups were all lower than those when entering the group, while albumin (ALB), cholinesterase (CHE) and prothrombin (PTA) were all higher than those when entering the three groups, and the biochemical response indexes were compared among the three groups, the differences were statistically significant (all P ＜ 0.05). In addition, ALT and TBil of group C were lower than those of group A and B, while ALB, CHE and PTA were higher than those of group A and B (P ＜ 0.05). After 12 and 24 months of treatment hyaluronic acid (HA), layer mucins (LN), collagen type Ⅳ (ⅣC), collagen type Ⅲ (PCⅢ) of three groups were lower than those when entering the group, and the hepatic fibrosis indexes were compared among the three groups, the differences were statistically significant (P ＜ 0.05), and HA, LN, Ⅳ C, PC Ⅲ of group C were lower than those of group A and B (P ＜ 0.05), after treatment HBeAg/Ab conversion in each group was lower than that before treatment (P ＜ 0.05), and group C was lower than group A and B (P ＜ 0.05). Among the 56 patients who passed the risk period, there was no statistically significant difference in liver histological score between group C and group A, group B before treatment (P ＞ 0.05). The total SSS score of inflammation and liver fibrosis after treatment was lower than that before treatment, and the total SSS score of group C was lower than that of group A and B (P ＜ 0.05). Conclusion The combined treatment of “three antibodies” can significantly improve liver function, liver inflammation, liver fibrosis and inhibition of viral replication, and improve the overall treatment efficiency and quality of life.

Key words： Hepatitis B hepatic failure Anti-virus Anti-inflammatory Anti fibrosis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	MO Shizao1 WANG Zhenchang2 LYU Yanhang3 WU Shanshan3 WEI Qinying2 PENG Li′na1

Cite this article:

MO Shizao1 WANG Zhenchang2 LYU Yanhang3 WU Shanshan3 WEI Qinying2 PENG Li′na1. “Three antibodies” intervention treatment and follow-up for hepatitis B liver failure survivors[J]. 中国医药导报, 2020, 17(23): 102-106.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2020/V17/I23/102

[1] 林锋.肝衰竭的临床诊断、预后评估和治疗进展.[J].临床肝胆病杂志，2016，32（9）：1678-1683.
[2] Coppola N，Pascalis SD，Onorato L，et al. Hepatitis B virus and hepatitis C virus infection in healthcare workers [J]. World J Hepatol，2016，8（5）：273-281.
[3] Carrier P，Debette-Gratien M，Jacques J，et al. Cirrhotic patients and older people [J]. World J Hepatol，2019，11（9）：663-677.
[4] Wong D，Littlejohn M，Yuen L，et al. HBeAg levels at week 24 predict response to 8 years of tenofovir in HBeAg-positive chronic hepatitis B patients [J]. Aliment Pharmacol Ther，2018，47（1）：18-26.
[5] 陆伦根，尤红，谢渭芬，等.肝纤维化诊断及治疗共识（2019年）[J].临床肝胆病杂志，2019，35（10）：2163-2172.
[6] 李军祥，陈誩，姚树坤.肝纤维化中西医结合诊疗共识意见（2017年）[J].中国中西医结合消化杂志，2017，25（12）：895-900.
[7] 王贵强，王福生，成军，等.慢性乙型肝炎防治指南（2015年更新版）[J].临床肝胆病杂志，2015，31（12）：1941-1960.
[8] 曾静，范建高.脾脏硬度检测在慢性肝病无创诊断中的应用[J].实用肝脏病杂志，2015，18（2）：209-212.
[9] Prodeau M，Drumez E，Duhamel A，et al. An ordinal model to predict the risk of symptomatic liver failure in patients with cirrhosis undergoing hepatectomy [J]. J Hepatol，2019，10（18）：1765-1782.
[10] 徐晖，潘成，何雪明，等.血浆置换对肝衰竭患者血清炎症因子表达的影响[J].中外医学研究，2018，16（10）：11-13.
[11] 刘春涛，武瑞，俞海燕，等.血浆透析滤过对慢加急性肝衰竭患者血清细胞因子水平及预后的影响[J].中国现代医生，2018，56（29）：13-16.
[12] Ashtari S，Pourhoseingholi MA，Sharifian A，et al. Hepatocellular carcinoma in Asia：Prevention strategy and planning [J]. World J Hepatol，2015，7（12）：1708-1717.
[13] Marcellin P，Ahn SH，Chuang WL，et al. Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B [J]. Aliment Pharmacol Ther，2016，44（9）：110-118.
[14] 苏金花，罗新.血清免疫球蛋白测定在肝衰竭的诊断价值[J].中国医药科学，2018，8（5）：137-139.
[15] 马磊.血清免疫球蛋白检验在肝衰竭诊断价值分析[J].当代医学，2019，25（19）：125-127.
[16] 黄宇，邓鑫，梁健.中西医结合药物治疗乙肝肝纤维化的研究进展[J].辽宁中医杂志，2018，45（4）：878-882.
[17] 张连俊，左亚东.中医药治疗慢性乙型肝炎肝纤维化的研究进展[J].中医临床研究，2015，7（2）：145-147.
[18] 张玉玲，闫雪华，谢青.中药联合抗病毒药物治疗HBV所致肝纤维化的研究进展[J].西部中医药，2019，32（6）：149-151.
[19] 罗艳，孟庆玉，李文莉，等.HPLC-DAD法同时测定复方益肝灵胶囊中水飞蓟宾和五味子醇甲的含量[J].中国药师，2013，16（12）：1797-1799.
[20] 郭璐.恩替卡韦联合复方益肝灵胶囊治疗慢性乙型肝炎肝纤维化51例疗效观察[J].中国现代药物应用，2016， 10（3）：10-12.
[21] 吕艳杭，吴姗姗，王振常.阿德福韦酯联合柔肝化纤颗粒治疗慢性乙型肝炎肝硬化临床效果[J].中国医药导报，2019，16（32）：107-110.
[22] 吕艳杭，吴姗姗，王振常，等.柔肝化纤颗粒联合骨髓间充质干细胞移植治疗乙肝肝硬化的临床观察[J].中医药导报，2019，25（20）：115-118.
[23] 吴姗姗，吕艳杭，王振常等. 壮方柔肝化纤颗粒治疗肝肾阴虚型乙肝肝硬化腹水的效果[J].中国医药导报，2020， 17（1）：122-125.
[24] 熊明鹏，王振常，黄晶晶.柔肝化纤颗粒联合粒细胞集落刺激因子治疗慢性乙型肝炎肝衰竭的疗效观察[J].辽宁中医杂志，2017，44（9）：1908-1910.
[25] 韦冬珏，叶冬梅，张凤英，等.中药复方柔肝化纤颗粒干预肝纤维化模型大鼠肝脏微循环障碍的变化[J].中国组织工程研究，2019，23（3）：453-457.